Kamada Ltd. develops, produces and markets specialty therapeutics, including specific immunoglobulins and other prescribed medicines, using sophisticated chromatographic purification technology. Utilizing its proprietary know-how, Kamada manufactures 10 high quality and highly safe biopharmaceuticals. Kamada flagship product - AAT, for the treatment of Congenital Emphysema - is approved for Phase III of clinical testing by the FDA, and is already administered in a number of countries. Kamada is currently working on the next generation AAT, administered by inhalation. With distribution channels in more than 15 countries, Kamada also provides R&D services for plasma-derived products to third parties.

Founded in 1990, Kamada successfully completed an initial public offering in 2005, and is now traded at the Tel Aviv Stock Exchange (KMDA). Over the years, Kamada has established a prominent presence within Israel抯 distinguished pharmaceutical industry community. Kamada will keep excelling in the development, production and distribution of unique pharmaceuticals which enable better quality of life and save lives.